aTyr Pharmaceuticals (ATYR) - מקדם חוב לטווח ארוך להון

aTyr Pharma, Inc. (ATYR) is advancing clinical trials of tRNA synthetases to combat sarcoidosis while simultaneously diversifying its portfolio toward oncology. The long-term debt-to-net asset ratio provided by GURU.Markets demonstrates financial stability, where the value of 0.19 characterizes this level. Therapy for fibrotic pathologies ensures stable demand and long-term margins due to the uniqueness of the proposed treatment methods.

The efficiency of the operating model directly impacts the sustainability of the debt load. This indicator measures the proportion of liabilities with a maturity of over one year relative to equity. The stable US legal framework and the humanitarian status of aTyr Pharma (ATYR) developments minimize default risks. Low financial leverage ensures financial security during drug development. Evaluate the trend of this long-term debt-to-equity ratio on this chart.